Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus palbociclib and letrozole versus placebo plus palbociclib and letrozole in endocrine-sensitive PIK3CA-mutant HR-positive HER2-negative advanced breast cancer
CTR20250874Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of inavolisib in breast cancer, sponsored by Roche. Started Mar 2025; status: active.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20250874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250874.